Floatz Rating
B56/100
Confidence
Indicative
Sponsor
CanariaBio Inc.
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
48High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04498117CT.gov Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery | — | Active Not Recruiting | — | — | — |
NCT03162562CT.gov The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer | — | Terminated | — | — | — |
NCT01616303CT.gov A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer | — | Completed | — | — | — |
NCT00034138CT.gov A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma | — | Terminated | — | — | — |
NCT00034372CT.gov Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian Carcinoma | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ovarian Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Oregovamab (this asset) | CanariaBio Inc. | P3 | B · 56 |
| Adriamycin | GlaxoSmithKline | P4 | BBB |
| Carboplatin | Eli Lilly and Company | P3 | BB |
| Pazopanib | The Christie NHS Foundation Trust | P2 | BB |
| Canfosfamide | Telik | P3 | BB |
| Niraparib | GlaxoSmithKline | P4 | BB |
| Docetaxel | Merck Sharp & Dohme LLC | P2 | BB |
| Trabectedin | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | P3 | B |
| Nogitecan | GlaxoSmithKline | P3 | B |
+42 more in the Ovarian Neoplasm cohort
Other indications for Oregovamab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Peritoneal Carcinoma | — | P3 | B · 56 |
| Ovarian Serous Adenocarcinoma | — | P3 | B · 56 |
| Ovarian Carcinoma | — | P3 | CCC · 54 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Oregovamab in Ovarian Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g1-anti-human-ca125-carbohydrate-antigen-mouse-monoclonal-b4313gamma1-chain-disulphide-with-mouse-monoclonal-b4313kappa-chain-dimer-ovarian-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →